41 reports

  • Profiles of Tuberculosis Drugs Producers
  • Tuberculosis Treatment Drugs Market Overview

China’s demand for Tuberculosis Treatment Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports,...

  • Tuberculosis
  • China
  • Demand
  • Guangzhou Baiyunshan Pharmaceutical Co., Ltd.
  • Shandong Lukang Pharmaceutical Co., Ltd
  • Tuberculosis Treatment Drugs Market Overview
  • Tuberculosis Treatment Drugs Market Overview

This study focuses on China’s Tuberculosis Treatment Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the...

  • Tuberculosis
  • China
  • Demand
  • Trade
  • Chongqing Huapont Pharmaceutical Co., Ltd
  • Profiles of Tuberculosis Drugs Producers
  • Chapter VII TUBERCULOSIS TREATMENT DRUGS PRODUCER DIRECTORY

This study focuses on China’s Tuberculosis Treatment Drugs industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy....

  • Tuberculosis
  • China
  • Guangzhou Baiyunshan Pharmaceutical Co., Ltd.
  • Shandong Lukang Pharmaceutical Co., Ltd
  • Shenyang Shuangding Pharmaceutical Co., Ltd.

Tuberculosis Drugs Market: Global Industry Analysis, Trends, Market Size and Forecasts up to 2024 ##.

  • Pathology
  • Tuberculosis
  • APAC
  • World
  • Demand

Based on Type, the market is categorized into Latent Tuberculosis, Active Tuberculosis and Drug-resistant Tuberculosis.

  • Anti-Infective
  • Tuberculosis
  • World
  • Forecast
  • Market Size

Current scientific views on epidemiology and etiology are provided for Adenovirus, Influenza, Legionella, Mononucleosis, Mycoplasma, Pneumonia, RSV and Tuberculosis.

  • Tuberculosis
  • Europe
  • Japan
  • United States
  • Demand

North America tuberculosis Drugs/ Therapeutics market, 2014 - 2025 (USD Million) ##. ##. ## U. S. ##. ##. ##. ## U. S. tuberculosis Drugs/ Therapeutics market, 2014 - 2025 (USD Million) ##. ##. ## Canada ##. ##. ##. ## Canada tuberculosis Drugs/ Therapeutics market, 2014 - 2025 (USD mil

  • Therapy
  • Tuberculosis
  • United States
  • Forecast
  • Market Size

Current scientific views on epidemiology and etiology are provided for Adenovirus, Influenza, Legionella, Mononucleosis, Mycoplasma, Pneumonia, RSV and Tuberculosis.

  • Infectious Disease
  • Respiratory Disease
  • Tuberculosis
  • Europe
  • Demand
  • 6.1.1 May 21, 2018: Oxford Immunotec's T-SPOT.TB Test Included in the World Health Organization's First-Ever Essential Diagnostics List

" Despite steady progress in reducing the burden of tuberculosis in recent decades, TB remains a major global health problem and one of the top ## causes of death worldwide, " said Dr.

  • Tuberculosis
  • United Kingdom
  • Market Size
  • DENTSPLY Sirona Inc.
  • Ivoclar Vivadent AG
  • PULMONARY TUBERCULOSIS THERAPEUTICS, GLOBAL, CLINICAL TRIALS BY PHASE (%), 2018*
  • PULMONARY TUBERCULOSIS THERAPEUTICS, GLOBAL, CLINICAL TRIALS IN PROGRESS BY PHASE, 2018*

Pulmonary Tuberculosis Global Clinical Trials Review, H1, 2018 Summary GlobalData’s clinical trial report, “Pulmonary Tuberculosis Global Clinical Trials Review, H1, 2018" provides an overview of Pulmonary Tuberculosis clinical trials scenario.This report provides top line data relating to the clinical...

  • Anti-Infective
  • Clinical Trial
  • Tuberculosis
  • World
  • Product Initiative
  • MYCOBACTERIUM TUBERCULOSIS INFECTIONS THERAPEUTICS, GLOBAL, CLINICAL TRIALS IN PROGRESS BY PHASE, 2018*
  • MYCOBACTERIUM TUBERCULOSIS INFECTIONS THERAPEUTICS CLINICAL TRIALS, GLOBAL, KEY SPONSORS, 2018*

Mycobacterium tuberculosis Infections Global Clinical Trials Review, H1, 2018 Summary GlobalData’s clinical trial report, “Mycobacterium tuberculosis Infections Global Clinical Trials Review, H1, 2018" provides an overview of Mycobacterium tuberculosis Infections clinical trials scenario.This report...

  • Anti-Infective
  • Clinical Trial
  • Infectious Disease
  • Tuberculosis
  • World
  • DRUG FOR TUBERCULOSIS
  • TUBERCULOSIS VACCINE - DRUG PROFILE

Tuberculosis - Pipeline Review, H1 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Tuberculosis - Pipeline Review, H1 2018, provides an overview of the Tuberculosis (Infectious Disease) pipeline landscape. Tuberculosis, commonly known as TB,...

  • Pathology
  • Tuberculosis
  • Vaccine
  • United States
  • TB Drug Development, Inc.

The report focuses on drugs and therapies being evaluated for Mycobacterium Tuberculosis Infections treatment in active clinical development phases including phase ##, phase ##, phase ## and phase ## clinical trials.

  • Clinical Trial
  • Pathology
  • Tuberculosis
  • AERAS ENTERS INTO CO-DEVELOPMENT AGREEMENT WITH TIANJIN CANSINO FOR TUBERCULOSIS VACCINE
  • AERAS ENTERS INTO R&D AGREEMENT WITH GLAXOSMITHKLINE VACCINES TO DEVELOP TUBERCULOSIS VACCINE

Summary Aeras Global TB Vaccine Foundation Inc (Aeras) is a non-profit biotech organization that develops tuberculosis (TB) vaccines.The organization offers TB vaccine candidates, preclinical candidates and vaccine candidates. Its services include portfolio management, preclinical research, clinical trials, research...

  • Pathology
  • Pharmaceutical
  • Tuberculosis
  • Vaccine
  • World
  • Tuberculosis
  • Small Molecule to Inhibit F0F1-ATP Synthase for Tuberculosis - Drug Profile

H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) - Pipeline Review, H1 2018 Summary According to the recently published report ’H+ Transporting Two Sector ATPase - Pipeline Review, H1 2018’; H+ Transporting...

  • Tuberculosis
  • United States
  • World
  • Product Initiative
  • Lycera Corp.
  • May 04, 2017: Spero Therapeutics Receives Grant from National Institutes of Health to Explore Novel Treatment Combinations for Tuberculosis
  • May 30, 2017: Spero Therapeutics Presents New Data on SPR720 at ASM Microbe 2017

DNA Gyrase Subunit B (EC 5.99.1.3) - Pipeline Review, H2 2018 Summary DNA Gyrase Subunit B (EC 5.99.1.3) pipeline Target constitutes close to 6 molecules. The latest report DNA Gyrase Subunit B (EC 5.99.1.3) - Pipeline Review, H2 2018, outlays comprehensive information on the DNA Gyrase Subunit B...

  • Tuberculosis
  • United States
  • World
  • Product Initiative
  • Spero Therapeutics, LLC
  • EPISTEM HOLDINGS ENTERS INTO CO-MARKETING AGREEMENT WITH XCELRIS LABS FOR MOLECULAR TUBERCULOSIS DIAGNOSTIC TEST
  • EPISTEM ANNOUNCES PRIVATE PLACEMENT OF SHARES FOR US$7 MILLION

Summary genedrive plc (genedrive), formerly Epistem Holdings plc is a molecular diagnostics company. The company focuses on the development and commercialization of simple to use “point of need” system or point of care diagnostics platform for the diagnosis of infectious diseases and use in patient genotyping, pathogen...

  • Tuberculosis
  • APAC
  • United Kingdom
  • United States
  • World
  • Indication
  • MBIO DIAGNOSTICS INC PIPELINE PRODUCTS BY INDICATION

Summary MBio Diagnostics Inc (MBio) is a medical device company that offers clinical diagnostics and sample testing solutions.The company offers MBio multiplex analyzer and disposable cartridges. Its MBio Array System is a fluorescence immunoassay system that provides measurement of analytes from a single sample.The...

  • Diagnostics
  • Tuberculosis
  • United States
  • Litigation And Patent
  • MBio Diagnostics, Inc.
  • Infectex Enters Into Licensing Agreement With Qurient For Tuberculosis Drug Q203
  • Jun 22, 2017: Infectex Successfully Completes Phase 1 Clinical Study of Q203 for Treatment of Tuberculosis

Summary Qurient Co Ltd (Qurient) is a pharmaceutical company that offers development of new drugs for unmet medical needs.The company provides portfolio of pipeline products such as Q301, Q203, Q701, 5LO INH and CDK7 INH, among others. It is developing products for the treatment of atopic dermatitis; extensively...

  • Pharmaceutical
  • Tuberculosis
  • South Korea
  • Company
  • Qurient Co., Ltd.
  • IN OCTOBER, THE COMPANY LAUNCHED QUANTIFERON-TB GOLD PLUS, A BLOOD TEST FOR TUBERCULOSIS (TB) INFECTION IN THE US.
  • REGULATORY APPROVAL

Qiagen NV (QIA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations.The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The...

  • Molecular Diagnostic
  • Tuberculosis
  • United States
  • Company Financials
  • QIAGEN N.V.
  • SANOFI ENTERS INTO RESEARCH AGREEMENT WITH TB ALLIANCE TO ADVANCE TREATMENTS FOR TUBERCULOSIS
  • NOVARTIS ENTERS INTO LICENSING AGREEMENT WITH GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT FOR TUBERCULOSIS DRUGS

Summary Global Alliance for TB Drug Development (TB Alliance) is a non-profit organization that discovers and develops drugs to treat tuberculosis.The organization’s products include natural products, rifampin, pyrazinamide, isoniazid, macrokuds, ethambutol, and topoisomerase inhibitors. It offers biomakers and lab...

  • Pathology
  • Tuberculosis
  • World
  • Company
  • TB Drug Development, Inc.
  • JANSSEN PHARMA ENTERS INTO LICENSING AGREEMENT WITH PHARMSTANDARD FOR BEDAQUILINE, ANTI-TUBERCULOSIS DRUG
  • JANSSEN PHARMA ENTERS INTO AGREEMENT WITH FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS

Summary Janssen Pharmaceutica NV (Janssen Pharmaceutica), a subsidiary of Johnson & Johnson is a drug development and manufacturing company that discover, develop, and produce medicines and therapeutic solutions.The company provides products such as human medicine products, veterinary products, and preservation and material...

  • Tuberculosis
  • Belgium
  • United States
  • Company
  • Janssen Biotech, Inc.
  • Clinical Trial profile. 597 Trial Title
  • Official Title

Mycobacterium Infections Global Clinical Trials Review, H1, 2018 Summary GlobalData’s clinical trial report, “Mycobacterium Infections Global Clinical Trials Review, H1, 2018" provides an overview of Mycobacterium Infections clinical trials scenario.This report provides top line data relating to...

  • Clinical Trial
  • Infectious Disease
  • Pharmaceutical
  • Tuberculosis
  • World
  • VENTURE FINANCING
  • Sequella Enters Into Licensing Agreement With Pfizer For Sutezolid

SQ## could replace one or more of the current TB drugs, simplify therapy, and shorten current treatment time.

  • Tuberculosis
  • Russia
  • United States
  • World
  • Deals & Alliance
  • Mar 24, 2018: Multidisciplinary Consortium Announces Launch of PITBUL, an International Collaboration for the Development of Ultrafast Tuberculosis Diagnostics
  • PITBUL ULTRAFAST TB TEST - PRODUCT DESCRIPTION

Summary GNA Biosolutions GmbH (GNAB) is an assays and instruments development company that develops assays and instruments for ultra-fast molecular pathogen detection of biomolecules through its technology.The company also develops rapid diagnostic DNA-based laser-heated nanoparticles. It uses PCR (Polymerase Chain...

  • Antibiotic Resistance
  • In Vitro Diagnostics
  • Tuberculosis
  • Company
  • Product Initiative
  • Function
  • AVISA PHARMA INC PIPELINE PRODUCTS BY INDICATION

Summary Avisa Pharma Inc (Avisa Pharma) is a medical device company that develops breath tests system for the diagnosis of pulmonary infections.The company provides product such as avisa breath test kit, which is designed to detect respiratory bacterial infections in the lung and other metabolic diseases; and avisar spec,...

  • Pathology
  • Tuberculosis
  • United States
  • Product Initiative
  • Avisa Pharma Inc.

Tuberculosis ## Viral Infections ## Human Papilloma Virus Infection ## John Cunningham Virus Infection ## Leishmaniasis ## Liver Cancer ## Lung Cancer ## Lyme Disease ## Malaria ## Melanoma ## Pancreatic Cancer

  • DNA
  • Tuberculosis
  • United States
  • Company
  • Trovagene, Inc.
  • TNP-2092 - DRUG PROFILE

In September 2006, Cumbre Pharmaceuticals Inc has entered into agreement with Global Alliance for TB Drug Development, a non-profit product development partnership for new tuberculosis (TB) drugs, to develop new agents for tuberculosis therapy.

  • Tuberculosis
  • United States
  • World
  • Product Initiative
  • AmpliPhi Biosciences Corporation
  • Mar 12, 2018: Molecular doorstop could be key to new tuberculosis drugs

Summary Rockefeller University (Rockefeller) is a biomedical research university that offers graduate and postdoctoral educational programs.The university offers educational courses in the fields of biomedical sciences, chemistry, bioinformatics and physics. It conducts clinical studies in the areas of addictive...

  • Pharmaceutical
  • Therapy
  • Tuberculosis
  • United States
  • Company
  • Feb 07, 2017: Researchers use tiny 3-D spheres to combat tuberculosis
  • Feb 07, 2017: Researchers use tiny 3-D spheres to combat tuberculosis

Summary University of Southampton (UOS) is an educational institution that offers education and research services.The institute provides educational programs in the fields of accounting and finance, acoustical engineering, aeronautics and astronautics, anthropology, archaeology, biochemistry, biology, biomedical sciences,...

  • Healthcare
  • Pharmaceutical
  • Therapy
  • Tuberculosis
  • United Kingdom